Pharmacogenomics

Key advantages

• Analysis of key pharmacogenes (e.g. CYP2D6, CYP2C19, SLCO1B1)

• Identification of variants affecting drug metabolism, efficacy, and toxicity

• Supports drug selection, dosage adjustment, and polypharmacy management

• Useful across multiple therapeutic areas: oncology, cardiology, psychiatry, and pain

• Available as stand-alone panel or integrated in broader clinical sequencing

• Reduces trial-and-error prescribing and adverse drug reactions

• Compatible with blood or saliva samples, non-invasive collection

• Actionable reporting based on CPIC guideline

Technical specifications

• Sample type: Whole blood, saliva, buccal swab

• Genotyping methods: NGS panel

• Genes covered: CYP2D6, CYP2C19, CYP3A4, SLCO1B1, TPMT, UGT1A1, VKORC1, and others

• Sequencing depth: ≥100x for high-confidence variant calling

• Output files: FASTQ, VCF, genotype/phenotype interpretation report

• Bioinformatics pipeline: allele and variant calling

• Report formats: Clinician-ready PDF, optional clinical consultation